Origin of MMP-8 and Lactoferrin levels from gingival crevicular fluid, salivary glands and whole saliva.

Biological markers Chronic periodontitis Gingival crevicular fluid Lactoferrin Matrix metalloproteinase-8 Periodontal pathogens

Journal

BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684

Informations de publication

Date de publication:
05 08 2021
Historique:
received: 07 04 2021
accepted: 12 07 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 10 8 2021
Statut: epublish

Résumé

Pathologically elevated levels of matrix metalloproteinase-8 (MMP-8) and Lactoferrin in oral fluids have been associated with the presence of gingivitis/periodontitis. This study aimed to assess the origin of MMP-8 and Lactoferrin in periodontitis patients and to identify the degree to which conventional clinical parameters correlate with their presence. A total of ten periodontitis and ten healthy patients were included in this study. Whole saliva (stimulated and unstimulated), parotid/sublingual glandular fluid and gingival crevicular fluid from pockets and sulci were tested for MMP-8 and Lactoferrin and protein concentrations were quantified using an ELISA assay. Clinical parameters were checked for potential associations with MMP-8 and Lactoferrin levels. Periodontal patients presented higher concentrations of MMP-8 and Lactoferrin in pockets than other sources (P = 0.03). Lactoferrin measurement was higher in the parotid compared to sublingual glandular fluid in periodontitis patients (P = 0.03). Increased probing pocket depth was positively correlated with high MMP-8 and Lactoferrin levels. Periodontal pockets appear to be the major source of active matrix metalloproteinase and Lactoferrin, which also may also enter the oral cavity through the salivary glands. Since clinically healthy sites in periodontitis patients also had elevated biomarker levels, gingival crevicular fluid biomarker testing may be more predictive of future tissue breakdown than conventional clinical parameters.

Sections du résumé

BACKGROUND
Pathologically elevated levels of matrix metalloproteinase-8 (MMP-8) and Lactoferrin in oral fluids have been associated with the presence of gingivitis/periodontitis. This study aimed to assess the origin of MMP-8 and Lactoferrin in periodontitis patients and to identify the degree to which conventional clinical parameters correlate with their presence.
METHODS
A total of ten periodontitis and ten healthy patients were included in this study. Whole saliva (stimulated and unstimulated), parotid/sublingual glandular fluid and gingival crevicular fluid from pockets and sulci were tested for MMP-8 and Lactoferrin and protein concentrations were quantified using an ELISA assay. Clinical parameters were checked for potential associations with MMP-8 and Lactoferrin levels.
RESULTS
Periodontal patients presented higher concentrations of MMP-8 and Lactoferrin in pockets than other sources (P = 0.03). Lactoferrin measurement was higher in the parotid compared to sublingual glandular fluid in periodontitis patients (P = 0.03). Increased probing pocket depth was positively correlated with high MMP-8 and Lactoferrin levels.
CONCLUSIONS
Periodontal pockets appear to be the major source of active matrix metalloproteinase and Lactoferrin, which also may also enter the oral cavity through the salivary glands. Since clinically healthy sites in periodontitis patients also had elevated biomarker levels, gingival crevicular fluid biomarker testing may be more predictive of future tissue breakdown than conventional clinical parameters.

Identifiants

pubmed: 34353321
doi: 10.1186/s12903-021-01743-5
pii: 10.1186/s12903-021-01743-5
pmc: PMC8340507
doi:

Substances chimiques

LTF protein, human 0
Lactoferrin EC 3.4.21.-
MMP8 protein, human EC 3.4.24.34
Matrix Metalloproteinase 8 EC 3.4.24.34

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

385

Informations de copyright

© 2021. The Author(s).

Références

Acta Odontol Scand. 2007 Feb;65(1):1-13
pubmed: 17354089
J Clin Periodontol. 1999 May;26(5):269-75
pubmed: 10355615
J Periodontal Res. 1970;5(1):36-41
pubmed: 4255144
J Clin Periodontol. 2005;32 Suppl 6:210-3
pubmed: 16128839
J Periodontal Res. 2012 Oct;47(5):655-60
pubmed: 22471324
Periodontol 2000. 1997 Jun;14:33-53
pubmed: 9567965
Mol Immunol. 2007 Mar;44(7):1498-508
pubmed: 17030385
Dis Markers. 2011;30(6):299-305
pubmed: 21725158
J Periodontol. 2015 May;86(5):611-22
pubmed: 25688694
Periodontol 2000. 2021 Jun;86(1):231-240
pubmed: 33690947
Dent Clin North Am. 2005 Jul;49(3):491-516, v
pubmed: 15978238
Contemp Clin Dent. 2014 Jan;5(1):25-30
pubmed: 24808691
Dis Markers. 2018 Nov 7;2018:4308291
pubmed: 30524520
Int Dent J. 1994 Apr;44(2):159-64
pubmed: 8063438
Int J Mol Sci. 2018 Dec 26;20(1):
pubmed: 30587811
Oral Dis. 2004 Nov;10(6):311-8
pubmed: 15533204
Ann R Australas Coll Dent Surg. 2004 Oct;17:30-4
pubmed: 16479852
J Clin Periodontol. 2002 Mar;29(3):224-32
pubmed: 11940142
J Periodontol. 2008 Aug;79(8 Suppl):1577-84
pubmed: 18673013
BMC Oral Health. 2015;15 Suppl 1:S5
pubmed: 26390822
Diagnostics (Basel). 2021 Mar 22;11(3):
pubmed: 33810094
J Clin Periodontol. 2011 May;38(5):434-41
pubmed: 21480939
Periodontol 2000. 2016 Feb;70(1):142-63
pubmed: 26662488
J Periodontal Res. 1993 Mar;28(2):130-6
pubmed: 8478785
J Periodontol. 2018 Jun;89 Suppl 1:S173-S182
pubmed: 29926951
Arch Oral Biol. 2018 Mar;87:115-124
pubmed: 29288920
Biotechnol Genet Eng Rev. 1996;13:19-50
pubmed: 8948108
Bull Exp Biol Med. 2012 May;153(1):72-6
pubmed: 22808498
J Clin Periodontol. 2019 Dec;46(12):1166-1182
pubmed: 31444912
J Clin Periodontol. 2011 Mar;38 Suppl 11:85-105
pubmed: 21323706
J Dent Res. 2011 Jun;90(6):752-8
pubmed: 21406610
J Sci Med Sport. 2011 Sep;14(5):424-34
pubmed: 21474377
J Appl Oral Sci. 2012 Mar-Apr;20(2):180-5
pubmed: 22666834
BMC Oral Health. 2015;15 Suppl 1:S6
pubmed: 26390888
Caries Res. 2015;49(1):1-8
pubmed: 25096527
J Dent. 2019 Jan;80 Suppl 1:S3-S12
pubmed: 30696553
Ann Periodontol. 1999 Dec;4(1):1-6
pubmed: 10863370
BMC Infect Dis. 2018 Jul 25;18(1):345
pubmed: 30045688
Ann N Y Acad Sci. 1993 Sep 20;694:72-7
pubmed: 8215087
J Periodontol. 2015 Jun;86(6):777-87
pubmed: 25741578
Ann N Y Acad Sci. 2007 Mar;1098:493-5
pubmed: 17435157
J Clin Periodontol. 2014 Feb;41(2):113-120
pubmed: 24303954
J Clin Periodontol. 2008 Aug;35(8):668-73
pubmed: 18564145
J Am Dent Assoc. 2006 Mar;137(3):322-9
pubmed: 16570465

Auteurs

Liza L Ramenzoni (LL)

Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland. liza.ramenzoni@zzm.uzh.ch.
Laboratory of Applied Periodontal and Peri-Implantitis Sciences, Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland. liza.ramenzoni@zzm.uzh.ch.

Deborah Hofer (D)

Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.

Alex Solderer (A)

Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.

Daniel Wiedemeier (D)

Statistical Services, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.

Thomas Attin (T)

Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.

Patrick R Schmidlin (PR)

Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.
Laboratory of Applied Periodontal and Peri-Implantitis Sciences, Clinic of Conservative and Preventive Dentistry, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, 8032, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH